TrialBlood advances2025

Phase 1 trial of durvalumab (anti-PD-L1) combined with lenalidomide in relapsed/refractory cutaneous T-cell lymphoma.

Christiane Querfeld et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.